Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a broad-spectrum intravenous antibiotic that has activity against Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus (MRSA), shows higher efficacy than the current benchmark (Wyeth's Zosyn/Tazocin) and is priced 50 percent higher than Zosyn/Tazocin would earn a higher patient share in the U.S. (50 percent) than in Europe (30 percent) for the treatment of hospital-acquired pneumonia. This is due to infectious disease specialists in Europe being more sensitive to pricing in their prescribing decisions.

The new report entitled Hospital-Acquired Pneumonia: Resistance Concerns Create Opportunities for New Broad-Spectrum Antibiotics also finds that Merck's Primaxin will remain Decision Resources' proprietary clinical gold standard through 2017. While some therapies in development for hospital-acquired pneumonia hold promise, most have efficacy, safety and tolerability and/or delivery issues when compared to Primaxin.

"Interviewed thought leaders believe that Primaxin has a better spectrum of activity than the benchmark therapy, Zosyn/Tazocin and perceive the agent to be more active against ESBL-producing E. coli and Klebsiella pneumoniae, Pseudomonas and Acinetobacter," stated Hemali Patel, Ph.D., analyst at Decision Resources. "Prescribers we surveyed agree that Primaxin is the most effective antibiotic for hospital-acquired pneumonia."

About the Report

Hospital-Acquired Pneumonia: Resistance Concerns Create Opportunities for New Broad-Spectrum Antibiotics is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:     Natalia Morales                              Elizabeth Marshall   Decision Resources                           Decision Resources, Inc.   781-296-2691                                 781-296-2563   nmorales@dresources.com                      emarshall@dresources.com 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources

CONTACT: Natalia Morales of Decision Resources, +1-781-296-2691,
nmorales@dresources.com, or Elizabeth Marshall of Decision Resources, Inc.,
+1-781-296-2563, emarshall@dresources.com

A First-Line Therapy for Renal Cell Carcinoma that can Increase Overall Survival when Compared with Sutent Would Earn a Higher Patient Share in the United States Than in Europe

View Now